Scoop: MedImmune chief Bahija Jallal is leaving AstraZeneca and joining the trek into biotech
Six years after AstraZeneca’s then new CEO Pascal Soriot named Bahija Jallal president of the big MedImmune subsidiary in Gaithersburg, MD, putting her at the center of the company’s R&D turnaround plans, the longtime pharma exec is joining the great migration of industry professionals to biotech.
Jallal is taking the helm at Immunocore next week, a prominent TCR player in the UK which has been going through a remarkable shakeup after the original team under CEO Eliot Forster — now chief at F-star — either left or were forced out. Immunocore was able to raise $320 million a little more than 3 years ago — a time when that kind of money was still able to cause astonishment in the industry.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.